The FDA has relaxed a clinical hold on clinical trials of Novartis' intrathecal formulation of spinal muscular atrophy (SMA) gene therapy Zolgensma, allowing a new phase 3 trial to get underway.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback